James C. Clemmer - Jul 19, 2023 Form 4/A - Amendment Insider Report for ANGIODYNAMICS INC (ANGO)

Role: President and CEO, Director
Signature: /s/ Stephen A. Trowbridge, Attorney in Fact
Stock symbol: ANGO
Transactions as of: Jul 19, 2023
Transactions value $: -$305,920
Form type: 4/A - Amendment
Date filed: 9/21/2023, 09:07 PM
Date Of Original Report: Jul 26, 2023
Previous filing: Jul 18, 2023
Next filing: Jul 25, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANGO	Common Stock	Options Exercise	$0	+69.7K	+13.17%	$0.00	599K	Jul 19, 2023	Direct	F1
transaction	ANGO	Common Stock	Tax liability	-$306K	-34.3K	-5.73%	$8.92	564K	Jul 19, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANGO	Performance Right	Options Exercise	$0	-109K	-100%	$0.00^*	0	Jul 19, 2023	Common Stock	109K		Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This acquisition of 69,676 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.
F2	The exempt disposition of 34,296 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.
F3	On July 14, 2020, the reporting person received a target grant of 108,871 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 69,676 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

Remarks:

This Form 4/A is being filed to correct the number of shares received by the Reporting Person and subsequently sold to satisfy tax withholding obligations in connection with the vesting and settlement of performance share units on 07/19/2023 and provides corrected amounts in Columns 4 and 5 of Table I.